Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
938 Views
eMediNexus 27 June 2018
A study published in Journal of the American College of Cardiology evaluated the safety and efficacy of rosuvastatin in preventing contrast-induced acute kidney injury (CI-AKI) in patients with diabetes mellitus (DM) and chronic kidney disease (CKD). This randomized study enrolled 2,998 patients with type-2 DM and concomitant CKD who were undergoing coronary/peripheral arterial angiography with or without percutaneous intervention. These patients were either administered rosuvastatin, 10 mg/day, for 5 days (2 days before, and 3 days after procedure) or standard-of-care. The results revealed that patients in the rosuvastatin group had notably lower incidences of CI-AKI than their controls. Furthermore, during the 30-day follow-up, the rate of worsening heart failure was considerably lower in the patients treated with rosuvastatin than that in the control group. Thus, it was concluded that rosuvastatin significantly reduced the risk of CI-AKI in patients with DM and CKD undergoing arterial contrast medium injection.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
High 1-hour Plasma Glucose: Early Indicator of Type 2 Diabetes Risk..
Maintaining Liver Health to Optimize Glycemic Outcomes in Early Type 2.....
Antibiotic Prescribing Practices for Pediatric Acute Otitis Media..
Hidden Hazard of Indoor Pollution in COPD..
Recognizing Pitfalls of Point-of-Care Lung Ultrasound..
{{Article_Title}}..
HMPV in India: Seven Cases Reported across Four States..
West Bengal Commission Fines Divine Nursing Home Rs 10 Lakh for Medical Negligence..
India Reports First Human Metapneumovirus (HMPV) Cases in Karnataka..
Two-Year-Old Dies after Wrong Injection Administered by Private Compounder in Jaisalmer..
'Law of the Land' Paramount for Blinkit's Ambulance Services, Says PiyushGoyal..